Case Report with Literature Review: Tumor-induced osteomalacia from a soft-tissue phosphaturic mesenchymal tumor of the trunk

Background: Tumor-induced osteomalacia (TIO), a type of acquired hypophosphatemic osteomalacia, is brought on by tumors producing excessive levels of fibroblast growth factor 23, which raises renal phosphorus excretion.

Methods: Through a review of the literature, we have outlined the clinical characteristics of 33 patients with soft-tissue TIO of the trunk and described a case of TIO brought on by a soft-tissue tumor on the back.

Results: A 63-year-old woman who had been experiencing generalized bone pain for approximately three years visited the hospital. Physical examination revealed a round mass on the back measuring approximately 2 × 2 cm. Laboratory tests showed low blood phosphorus, elevated synchronous urinary phosphorus, and elevated alkaline phosphatase levels. The mass was detected using magnetic resonance imaging and ultrasound, and it was subsequently surgically excised. Following surgery, phosphate levels returned to normal, bone pain was relieved, and pathology confirmed phosphaturic mesenchymal tumor (PMT). A literature review identified only 33 cases of soft-tissue TIO occurring in the trunk, with a mean age of 49.7 ± 15.6 years and a male-to-female ratio of 23:10. Bone pain was present in 91% of patients, and diagnostic delay of more than two years was observed in 72.4% of cases. The mean preoperative serum phosphorus level was 0.48 ± 0.137 mmol/L, and the median tumor size was 3 cm (IQR: 2–4.65 cm). Postoperative remission of biochemical indices and clinical symptoms was observed in 96.9% of patients, with no recurrence during the follow-up period. The majority of tumors (72.7%) were pathologically diagnosed as PMT.

Conclusion: Soft-tissue TIO of the trunk is rare. Clinicians should be alert to the possibility of TIO in patients with unexplained bone pain and hypophosphatemia and should promptly perform appropriate examinations to avoid missed diagnoses.

1 Introduction

Tumor-induced osteomalacia (TIO) is a type of acquired hypophosphatemic osteomalacia caused by excessive production of fibroblast growth factor 23 (FGF23) by tumors, leading to decreased renal reabsorption and increased urinary excretion of phosphorus. Clinically, patients present with symptoms such as weakness, bone pain, bone deformities, and multiple fractures. Once the tumor is removed, blood FGF23 levels decrease, blood phosphorus levels rise, and the condition improves markedly, with most patients achieving complete recovery. Although tumors causing TIO can occur in any part of the body, soft-tissue tumors of the trunk are rarely reported. Therefore, we present a case of TIO brought on by a phosphaturic mesenchymal tumor (PMT) in the soft tissues of the back and conduct an extensive review of the relevant published research.

2 Materials and methods

2.1 Case description

A 63-year-old woman was admitted to our department on June 10, 2021, with generalized bone pain that had persisted for approximately three years. The patient had sustained a right ankle fracture three years earlier following an accidental fall, which healed with conservative treatment. She developed generalized bone pain, which was initially present in the lower back before gradually spreading to the limbs. She was diagnosed with severe osteoporosis at several hospitals. She received treatment with oral alendronate as well as calcium and vitamin D supplementation, but the therapeutic outcomes were unsatisfactory. The pain gradually intensified, accompanied by fatigue. The symptoms began with weakness in both lower limbs, gradually developing into general weakness. She experienced increasing difficulty in getting up and turning over, and a wheelchair was needed for movement. She underwent lumbar internal fixation surgery for lumbar disc herniation at other hospitals more than a year earlier and was later admitted to our outpatient clinic in February with a diagnosis of bilateral rib fractures. She was managed conservatively at our hospital as an outpatient. She had no history of hypertension or diabetes mellitus and denied any family history of hereditary or infectious diseases, such as hepatitis. She had been menopausal for nearly 10 years. Physical examination revealed a rounded, soft, non-indurated, and movable mass on the back, measuring approximately 2 × 2 cm. There was tenderness in the spinous processes of the lumbar vertebrae. There was no deformity in the pelvis, but there was mild squeezing pain. A thoracic compression test (+) was conducted. The distance from the costal margin to the iliac spine was approximately 5–6 cm. We performed auscultation of the heart and lungs (-) and abdominal physical examination (-). The muscle strength of both upper limbs was grade V, and that of both lower limbs was grade IV. Physiological reflexes were present, but pathological signs were not elicited.

Laboratory tests upon admission and their results were: biochemical tests: blood, urine, and stool routine tests were normal. Blood phosphorus: <0.30 mmol/L, blood calcium: 2.10 mmol/L, 24-h urine phosphorus 15.3 mmol (synchronous blood phosphorus <0.3 mmol/L), 24-h urine calcium 2.31 mmol (synchronous blood calcium 2.10 mmol/L), alkaline phosphatase 265 IU/L (see Table 1), alanine aminotransferase 11 IU/L (7–40 IU/L), blood glucose 5.68 mmol/l (3.6–6.1 mmol/L), creatinine 56.6 µmol/L; blood gas analysis: blood pH was 7.426 (7.35–7.45), partial pressure of carbon dioxide was 4.38 kPa (4.26–5.99 kPa), and concentration of bicarbonate (cHCO₃-) was 21.2 mmol/L. Endocrine hormones: parathyroid hormone 10.4 pmol/L (synchronous blood calcium 2.31 mmol), growth hormone 0.256 ng/mL. The cortisol rhythm, insulin-like growth factor 1 (IGF-1), and thyroid function were all normal. Bone metabolism indicators: total vitamin D 12.87 ng/mL, β-collagen degradation products 0.570 ng/mL, total type I collagen amino-terminal elongated peptide 169.5 ng/mL, osteocalcin 14.36 ng/mL (7.7–21.7 ng/mL), and calcitonin 0.50 pg/mL.

Table 1

Table 1. Some laboratory indicators and reference ranges at admission.

Imaging studies showed generalized abnormalities of the skeletal system. The bone mineral density of the orthotopic lumbar vertebrae (L1–L4) was 0.716 g/cm², with a T-score of -3.3. A whole-body digital radiography (DR) scan showed degenerative changes in the pelvis; degenerative changes and osteoporosis in the lumbar spine; decreased bone mineral density of the thoracic and lumbar vertebrae with varying degrees of vertebral body flattening; and the presence of the “double-concave sign” in some vertebral bodies. Post-fixation changes were observed in the lumbar vertebrae (L3–L5), along with osteoporosis of the cranial vault bones and both metacarpals (Figures 1A–D).

Figure 1

Figure 1. (A) Left side of the skull on digital radiography (DR). (B) Orthostatic X-ray image of the left hand on DR. (C, D) DR thoracolumbar lateral film. (E, F) Ultrasound showed a hypoechoic mass in the subcutaneous fat layer of the right back, measuring approximately 23 × 12 × 20 mm in size, with a clear boundary. The mass was mainly internally hypoechoic and was surrounded by a liquid dark area. CDFI: Short linear blood flow signals can be seen in the periphery and inside. (G, H) 3.0T MRI chest plain scan: A nodular abnormal signal shadow was observed in the subcutaneous fat layer of the right back, approximately 14 × 21 mm in size. T1W1 showed a relatively low signal intensity, while T2W1 and fat compression showed a mixed high and low signal intensity. The shape was irregular and lobulated, closely adhering to the adjacent skin, with a clear and smooth residual edge. (I) The tumor was a soft gray-brown tissue, 3.0 × 3.0 × 2.0 cm in size. (J–L) Microscopic observation: The submitted tissue was composed of proliferating blood vessels and spindle cells, with unclear boundaries from the surrounding tissues. Blue-stained granular interstitial substances (stained with hematoxylin and eosin) could be seen between the spindle cells. Immunohistochemistry showed spore cells, Vim positivity, CD56 positivity, CD34 negativity, and Ki-67 positivity with a hotspot area of approximately 10%. (M–P) Immunohistochemical staining of FGF23, Ki67, SATB2, and SSTR2A (40×). (Q) The lateral lumbar spine X-ray of the patient 6 months after the operation.

Ultrasound of the mass on the back showed a hyperechoic lesion in the subcutaneous fat layer measuring approximately 23 × 12 × 20 mm, with clear boundaries and predominantly hyperechoic internal echoes, although its nature remained undetermined (Figures 1E, F). Magnetic resonance imaging (MRI) of the chest revealed a nodular abnormal signal shadow in the subcutaneous fat layer on the right side of the back, measuring approximately 14 × 21 mm, with a relatively low signal intensity on T1-weighted images and mixed high and low signal intensity on T2-weighted images and fat-suppressed sequences. The mass exhibited an irregular, lobulated morphology and was closely adherent to the adjacent skin, with the remaining edges appearing clear and smooth (Figures 1G, H).

The patient has been diagnosed with osteoporosis multiple times in the past. However, generalized bone pain, fatigue, and decreased muscle strength were evident during physical examination, which do not match the clinical manifestations of osteoporosis. The patient’s laboratory tests showed significant hypophosphatemia, a marked increase in synchronous urinary phosphorus, and elevated alkaline phosphatase, none of which support the diagnosis of osteoporosis. Whole-body DR scans of some vertebrae revealed double concave changes, and lateral head films showed blurred trabeculae and other manifestations of osteomalacia, rather than characteristic changes of osteoporosis. The patient’s age of onset, clinical manifestations, laboratory tests, and DR manifestations supported the diagnosis of hypophosphate-osteomalacia in metabolic bone diseases and ruled out metabolic bone diseases caused by other diseases such as multiple myeloma, hypercortisolism, and hyperparathyroidism. The patient was middle-aged or older with no family history, and hereditary hypophosphatemic osteomalacia was not considered. If acidosis is absent, then hypophosphatemic osteomalacia caused by renal tubular acidosis should not be considered. Based on a comprehensive analysis, tumor-related hypophosphatemic osteomalacia was considered.

A mass can be palpated in the subcutaneous fat layer on the patient’s back. Given the superficial location of the mass, a localized lumpectomy was performed on June 23, 2021. During the operation, a transverse, shuttle-shaped incision approximately 4 cm in length was made along the dermatoglyphics, centered over the right back mass. The skin was incised to expose the mass, which was soft and well-defined. The mass, along with the surrounding fatty tissue, was excised using an electrocautery device, and the specimen was sent for pathological examination. Visual inspection of the excised tissue indicated a piece of grayish-brown tissue, 3.0 cm × 3.0 cm × 2.0 cm in size, and soft in texture. Microscopic observation: The resected tissue comprised proliferating blood vessels and spindle cells, with an indistinct boundary from the surrounding tissues. Blue-stained granular interstitium was seen between the spindle cells.

Postoperative pathology revealed the lesion to be consistent with a PMT (Figures 1I–L). Immunohistochemical staining demonstrated spindle cell Vim expression, neural cell adhesion molecule (CD56) expression, lack of cluster of differentiation 34 (CD34) expression, a Kiel antigen 67 (Ki-67) hotspot area of approximately 10%, as well as expression of FGF23, growth inhibitory receptor 2A (SSTR2A), and specialized AT-rich sequence-binding protein 2 (SATB2) (Figures 1M–P).

Blood phosphorus levels were assessed on the first postoperative day at 0.45 mmol/L (reference range: 0.85–1.51 mmol/L), on the second day at 0.68 mmol/L, and on the third postoperative day at 1.11 mmol/L, returning to normal levels (Figure 2). Six weeks after the operation, the blood phosphorus level was 1.51 mmol/L, and the urine phosphorus level was 8.2 mmol/24 h. The patient reported that the pain and fatigue throughout her body had significantly lessened compared to before. Considering that patients with TIO may develop bone starvation syndrome following an operation and that our patient was an older postmenopausal woman (1, 2), 0.6 g of calcium carbonate D3 (caltrate D) and 0.25 µg of calcitriol capsules were continuously administered after the operation. The patient’s pain and fatigue symptoms were basically relieved, and she could walk independently one month after the operation. Six months after the operation, the lateral DR lumbar spine X-ray was reexamined, and the cortical bone was thicker than that before the operation (Figure 1Q).

Figure 2

Figure 2. Three-day trend chart of changes in preoperative and postoperative serum phosphorus in patients.

The study received approval from our hospital’s institutional review board, and because of its retrospective nature, formal informed consent was not required from the patient.

2.2 Literature review

Soft-tissue TIO of the trunk includes TIO occurring in the chest, lungs, abdomen, breasts, and back (excluding the spine and ribs). A PubMed database search was conducted using the terms “tumor-induced osteomalacia,” “phosphaturic mesenchymal tumor,” and “oncogenic osteomalacia,” covering literature up to January 1, 2025. A total of 33 cases of soft-tissue TIO of the trunk were identified, with detailed information presented in Table 2.

Table 2

Table 2. Literature review of 33 cases of soft tissue TIO in the trunk.

2.3 Data collection

We collected data on age, sex, clinical characteristics, diagnostic delay time, serum phosphate level, diagnostic method, tumor location and size, treatment, outcome, follow-up duration, histological diagnosis, and immunohistochemistry from 33 patients with soft-tissue TIO of the trunk. Diagnostic delay time was defined as the interval from symptom onset to the diagnosis of TIO.

2.4 Statistical analysis

SPSS version 23 software was used to analyze the data. Normality was evaluated using the Shapiro-Wilk test. The mean ± standard deviation was used to represent data that fit a normal distribution, whereas the median and interquartile range (IQR) were used to represent data that did not.

3 Results

Thirty-three cases of soft-tissue TIO of the trunk (excluding the present study) were identified, and the detailed clinical characteristics of these patients are presented in Table 2. The mean age of the patients was 49.7 ± 15.6 years, and the male-to-female ratio was 23:10. The clinical presentations included pain in 30 of 33 cases (91%), fractures in 7 of 33 cases (21%), and malaise in 16 of 33 cases (48%). The tumor involved bone in 8 cases (24.2%) and was limited to soft tissue in the remaining 25 cases. A diagnostic delay of more than two years was observed in 72.4% of cases. The mean preoperative serum phosphorus level was 0.48 ± 0.137 mmol/L (reference range: 0.81–1.45 mmol/L), and the median tumor size was 3 cm (IQR: 2–4.65 cm). Tumor localization methods included physical examination (14 cases), 68 Gallium-DOTA-Tyr3-octreotate positron emission tomography - computed tomography (⁶⁸Ga-DOTATATE PET/CT) (8 cases), MRI (13 cases), computed tomography [(CT), 10 cases], bone scan (5 cases), PET-CT (4 cases), ¹⁸F-FDG PET/CT (4 cases), and ultrasound (2 cases).

For treatment, 32 patients underwent surgical resection, while one patient with metastatic undifferentiated embryonal hepatic sarcoma received chemotherapy. Clinical symptoms gradually improved, and biochemical indices returned to normal postoperatively in 31 patients. However, one patient died at the age of 18 years due to postoperative malignant transformation with multiple metastases. The median follow-up time of the 33 patients was 10 months (IQR: 3–24 months). Postoperative pathology in 72.7% of patients with TIO was reported as PMT or phosphaturic mesenchymal tissue tumor mixed connective tissue subtype (PMTMCT). The remaining tumor pathologies included two cases each of sarcoma, osteosarcoma, angioepithelial cell tumor, epithelioid hemangioendothelioma, and one case of fibrocystic breast nodule. Immunohistochemistry was missing in 23 of the 33 patients. The immunohistochemical results of the remaining patients demonstrated three cases of FGF23 positivity, three cases of CD34 positivity, two cases of vimentin positivity, and one case each of SSTR2A, CD31, FLI-1, ERG, P53, IgG4, and SMA positivity.

4 Discussion

Herein, we report a case of TIO caused by a soft tissue tumor in the back. We also reviewed cases of TIO that occurred in the trunk in the literature. Our patient presented with generalized bone pain and weakness in both lower extremities. Laboratory tests indicated hypophosphatemia, elevated simultaneous urinary phosphorus, and elevated alkaline phosphatase. Whole-body DR scans showed “double depression” in some vertebrae, and lateral head films also revealed blurred trabeculae and other characteristic changes of osteomalacia. Hypophosphatemic osteomalacia was considered. A mass was found in the back during physical examination, and its location and relationship to surrounding tissues were further evaluated using MRI. Based on the above clinical manifestations and laboratory tests, TIO was considered. Owing to the superficial location of the mass, we performed a direct resection. On the third day after surgery, the patient’s blood phosphorus level returned to normal, and the symptoms of bone pain and fatigue were significantly alleviated.

Postoperative pathology suggested a PMT. Immunohistochemistry showed spindle cells that were positive for Vim, CD56, Ki-67 (with a hotspot area of approximately 10%), FGF23, SSTR2A, and SATB2, but negative for CD34.

TIO is a rare disease, with an estimated prevalence of 0.70 per 100,000 population in one epidemiological study (35) and fewer than 1,000 cases reported worldwide (36). A study by Bosman et al. (37), which included 895 cases of TIO, showed that tumors can occur in any part of the body, with the most common locations being the lower extremities, head and neck, pelvis, and trunk in that order. Jan De Beur et al. (38) reported that TIO of the trunk accounted for only 14% of all TIO cases. Clinically, TIO should be considered in patients presenting with chronic bone pain, fatigue and weakness, and fragility fractures, and refinement of serum phosphate testing is recommended. Once biochemical results support a diagnosis of TIO, a combination of functional and anatomical imaging is required to localize the tumor. Unlike bone tumors, some soft-tissue tumors are relatively superficial, and careful physical examination is valuable in detecting these tumors. In this study, tumors were detected by physical examination in 42% of cases, which is higher than the 32.4% reported in the systematic review by Bosman et al. (37), suggesting that physical examination is particularly important in identifying superficial soft-tissue tumors. Primary care hospitals should identify suspected soft-tissue tumors during physical examination and evaluate their relationship to adjacent tissues using MRI or CT. If the physical examination is negative, then functional imaging should be performed to identify the approximate location of the tumor. Conventional Octreoscan SPECT/CT imaging (e.g., 99mTc-octreotide SPECT/CT imaging or 111In-octreotide SPECT imaging) improves tumor detection (39, 40), but its spatial resolution is limited. ⁶⁸Ga-DOTATATE, a ⁶⁸Ga-labeled somatostatin analog, binds to the PMT-expressed SSTR to localize tumors (41). In our study, ⁶⁸Ga-DOTATATE PET/CT successfully localized tumors in 24% of patients with trunk TIO. For lesions in deep or anatomically complex areas, ⁶⁸Ga-DOTATATE PET/CT is particularly advantageous (16). Hou et al. (42) showed that ⁶⁸Ga-DOTATATE-PET/CT had a sensitivity of 94.7%, which was higher than the sensitivity of Octreoscan SPECT/CT (86.3%) (43) and ¹⁸FDG-PET/CT (80.0%) (44). Global TIO guidelines recommend ⁶⁸Ga-DOTATATE PET/CT, ⁶⁸Ga-DOTANOC PET/CT, and ⁶⁸Ga-DOTATOC PET/CT as first-line functional imaging, followed by octreotide scans (99mTc- or 111In-pentetreotide scans) or FDG-PET (1).

Complete surgical resection is the preferred treatment option for TIO (45). In this study, 96.9% of patients experienced postoperative remission of biochemical markers and clinical symptoms with no recurrence during the follow-up period. Meanwhile, 3.1% developed metastatic tumors postoperatively, and 3.0% had metastases present at the time of initial diagnosis, for which chemotherapy was the treatment of choice. Studies have shown that limb soft-tissue tumors yield better surgical outcomes than intraosseous tumors associated with TIO (46). For patients with inoperable or metastatic TIO, treatment typically involves oral phosphate combined with osteotriol, although long-term use can lead to secondary hyperparathyroidism or renal calcification (47). Novel therapies, such as the anti-FGF23 monoclonal antibody, Burosumab, significantly improve biochemical markers and quality of life by restoring renal phosphorus reabsorption and vitamin D metabolism through FGF23 inhibition (48, 49). Crotti et al. (48) reported a case of a European patient who, after three unsuccessful surgeries, was treated with Burosumab for two years, resulting in significant improvement in both pain and blood phosphorus levels. However, Burosumab does not inhibit tumor progression, so patients should continue to pursue surgical resection while undergoing treatment. In cases where patients do not improve after surgery, clinicians should consider the possibility of multifocal tumors or malignant transformation. This study suggests that although most of the tumors causing TIO are benign, long-term follow-up remains essential after surgery.

Patients with TIO exhibit diverse tumor pathology, with most pathology reports identifying PMT or PMTMCT. The concept of PMT was first introduced by Weidner and Cruz (50) in 1987, who classified four morphological subtypes: PMTMCT, osteoblastoma-like, non-ossifying fibroma-like, and ossifying fibroma-like tumors (51). In 2004, Folpe et al. (52) further clarified that most PMTs can be categorized as the mixed connective tissue subtype. PMTs exhibit varied histological features. Tumor cells typically range from small round cells to short, spindle-shaped, fibroblast-like cells. These tumors are usually accompanied by numerous thick- and thin-walled small blood vessels of mesenchymal origin with diffuse infiltration. In some cases, osteoid and cartilaginous stroma, gravel-like calcifications, and osteoblastic giant cells are also observed (53). Due to its lack of specific histological features and considerable morphological overlap with other soft-tissue tumors, PMT is frequently misdiagnosed as hemangioma, ossifying fibroma, osteosarcoma, or chondrosarcoma (53). Immunohistochemistry aids in determining tumor pathology; however, studies on the immunophenotype of PMT remain limited both locally and internationally. According to the literature, PMTs express various immunohistochemical markers to differing extents, including FGF23, vimentin, NES, CD56, CD68, SMA, CD34, Bcl-2, D2-40, and CD99. Reported positivity rates include 88.4% for FGF23 (53), 90% for SATB2, and 79% for SSTR2A (54). In our cases, immunohistochemical staining was positive for FGF23, SSTR2A, and SATB2. Among the trunk cases analyzed, all three showed positive FGF23 immunohistochemical staining (3/3; 100%), and one case was positive for SSTR2A. Co-expression of FGF23 and SSTR2A is highly sensitive for diagnosing PMT but lacks specificity; however, negative results can effectively exclude PMT (55–57). A recent study by Agaimy et al. (54) further reported frequent expression of SATB2, CD56, and ETS-related gene (ERG) in PMT. Other supportive markers, including NSE, CD99, Bcl-2, and D2-40, are commonly positive, while SMA and CD34 may show focal expression (58). In contrast, S-100 protein, junctional proteins, and similar markers are typically not expressed (59). According to Chatterjee et al., SATB2+/ERG+/CD56+/S-100-/STAT6- is an immunophenotype that assists in distinguishing PMT from numerous histologic mimics (60). Compared with the immunophenotypes of other patients with TIO in the trunk and soft tissue, the immunophenotype of our patient (SATB2+/SSTR2A+/CD56+/FGF23+) was relatively complete, which is also a strong basis for diagnosis.

For patients with generalized bone pain and fatigue, completing the blood phosphorus test in a timely manner and considering the possibility of TIO are necessary. A comprehensive and detailed physical examination of the whole body is the simplest and most necessary localization method for diagnosis (61). For patients who are highly suspected of having TIO and superficial soft tissue masses, the masses can be completely removed. This is both a diagnostic and therapeutic method. Typical pathological features and comprehensive immunohistochemical analysis can help with the final diagnosis.

4.1 Study limitations

A key limitation of this study is the absence of FGF23 measurement, as it is not routinely tested at the authors’ hospital. Consequently, we were unable to observe its dynamic changes throughout all stages of the disease. In addition, no genetic testing was conducted on the patients and no further in-depth research was carried out.

5 Conclusion

We report a soft-tissue PMT in the trunk that resulted in TIO. Based on our case and a review of the relevant literature, we highlight three key points: First, complex imaging is not always necessary for patients with TIO, and the role of physical examination in localizing superficial soft-tissue PMTs should not be underestimated. Second, clinicians should remain vigilant for tumor-associated hypophosphatemic osteomalacia in patients presenting with unexplained bone pain and hypophosphatemia and should promptly conduct appropriate examinations to avoid missed diagnoses. Third, although the prognosis following PMT resection is generally favorable, long-term follow-up is essential to detect multifocal disease or malignant transformation at an early stage.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Medical Ethics Committee of Dongguan Hospital of Guangzhou University of Chinese Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HT: Writing – review & editing, Data curation, Writing – original draft, Methodology, Conceptualization. ZD: Data curation, Writing – original draft. LC: Writing – original draft, Data curation. WW: Data curation, Writing – original draft. YZ: Supervision, Writing – review & editing. YW: Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by the Dongguan High-level Health and Wellness Talent Introduction and Cultivation Project (21000033) of Yuqing Zhou.

Acknowledgments

We are grateful to the patient who kindly consented to the publication of this paper. We would like to thank Editage (www.editage.cn) for English language editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

TIO, Tumor-induced osteomalacia; PMT, phosphaturic mesenchymal tumor; PMTMCT, phosphaturic mesenchymal tissue tumor mixed connective tissue subtype; FGF23, fibroblast growth factor 23; DR, digital radiography; FDG, fluorodeoxyglucose; PET-CT, positron emission computed tomography; CT, computed tomography; MRI, magnetic resonance imaging; SSTR2A, growth inhibitory receptor 2A; SATB2, specialized AT-rich sequence-binding protein 2; SMA, smooth muscle actin; ERG, ETS-related gene; TmP/GFR, tubular maximum reabsorption of phosphate per glomerular filtration rate.

References

1. Jan De Beur SM, Minisola S, Xia W, Abrahamsen B, Body J, Brandi ML, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. (2023) 293:309–28. doi: 10.1111/joim.13593

PubMed Abstract | Crossref Full Text | Google Scholar

2. Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, et al. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. Can Med Assoc J. (2023) 195:E1333–48. doi: 10.1503/cmaj.221647

PubMed Abstract | Crossref Full Text | Google Scholar

3. Chen DW, Clines GA, Collins MT, Douyon L, and Choksi PU. A rare cause of atraumatic fractures: case series of four patients with tumor-induced osteomalacia. Clin Diabetes Endocrinol. (2020) 6:12. doi: 10.1186/s40842-020-00101-8

PubMed Abstract | Crossref Full Text | Google Scholar

4. DeWitt CA, Collins MT, and Cowen EW. Diffuse pain, hypophosphatemia, and a subcutaneous nodule. J Am Acad Dermatol. (2007) 57:509–12. doi: 10.1016/j.jaad.2007.05.010

PubMed Abstract | Crossref Full Text | Google Scholar

5. Gardner KH, Shon W, Folpe AL, Wieland CN, Tebben PJ, and Baum CL. Tumor-induced osteomalacia resulting from primary cutaneous phosphaturic mesenchymal tumor: a case and review of the medical literature. J Cutan Pathol. (2013) 40:780–4. doi: 10.1111/cup.12209

PubMed Abstract | Crossref Full Text | Google Scholar

6. Graham RP, Hodge JC, Folpe AL, Oliveira AM, Meyer KJ, Jenkins RB, et al. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Hum Pathol. (2012) 43:1334–8. doi: 10.1016/j.humpath.2011.11.020

PubMed Abstract | Crossref Full Text | Google Scholar

7. Gu J, Ge C, Joshi G, Most M, and Tai R. Phosphaturic mesenchymal tumor: two cases highlighting differences in clinical and radiologic presentation. Skeletal Radiol. (2024) 53:995–1002. doi: 10.1007/s00256-023-04462-w

PubMed Abstract | Crossref Full Text | Google Scholar

8. Habbsa S, Canakis A, George L, Thomas A, Hu Y, Cross RK, et al. A dancer with fractures: what lies beneath? Dig Dis Sci. (2023) 68:54–7. doi: 10.1007/s10620-022-07697-0

PubMed Abstract | Crossref Full Text | Google Scholar

9. Habra MA, Jimenez C, Huang S-CE, Cote GJ, Murphy WA, Gagel RF, et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract. (2008) 14:1108–14. doi: 10.4158/EP.14.9.1108

PubMed Abstract | Crossref Full Text | Google Scholar

10. Karaa-Zbidi N, Damade R, and Lhote F. faust fat free: une incapacité à marcher chez un homme de 41 ans. Rev Med Interne. (2016) 37:62–5. doi: 10.1016/j.revmed.2015.05.008

PubMed Abstract | Crossref Full Text | Google Scholar

11. Kaul M, Silverberg M, DiCarlo EF, Schneider R, Bass AR, and Erkan D. Tumor-induced osteomalacia. Clin Rheumatol. (2007) 26:1575–9. doi: 10.1007/s10067-006-0468-y

PubMed Abstract | Crossref Full Text | Google Scholar

12. Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K, et al. Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI. Endocrinol Diabetes Metab Case Rep. (2017) 2017:16-0005. doi: 10.1530/EDM-17-0005

PubMed Abstract | Crossref Full Text | Google Scholar

13. Zalewska E, Płoszaj-Neć M, Kaniuka-Jakubowska S, Orzechowska-Pawiłojć A, Śledziński M, Piskunowicz M, et al. Oncogenic osteomalacia — detection of the tumour site upon physical examination. Endokrynol Pol. (2022) 73(4):792–3. doi: 10.5603/EP.a2022.0013. VM/OJS/J/85971.

PubMed Abstract | Crossref Full Text | Google Scholar

14. Zura RD, Minasi JS, and Kahler DM. Tumor-induced osteomalacia and symptomatic looser zones secondary to mesenchymal chondrosarcoma. J Surg Oncol. (1999) 71:58–62. doi: 10.1002/(SICI)1096-9098(199905)71:1<58::AID-JSO12>3.0.CO;2-F

PubMed Abstract | Crossref Full Text | Google Scholar

15. Meng QH and Wagar EA. Severe hypophosphatemia in a 79-year-old man. Clin Chem. (2014) 60:928–31. doi: 10.1373/clinchem.2013.210534

PubMed Abstract | Crossref Full Text | Google Scholar

16. Mennetrey C, D’Journo XB, Burtey S, and Taïeb D. Oncogenic osteomalacia related to an intramuscular mesenchymal tumor of the scalene muscles. Kidney Int. (2021) 100:245. doi: 10.1016/j.kint.2020.12.009

PubMed Abstract | Crossref Full Text | Google Scholar

17. Oka M, Kamo T, Sasaki E, Kaji H, Nishizawa H, Imanishi Y, et al. A case of phosphaturic mesenchymal tumour (mixed connective tissue variant) that developed in the subcutaneous tissue of a patient with oncogenic osteomalacia and produced fibroblast growth factor 23. Br J Dermatol. (2007) 157:198–200. doi: 10.1111/j.1365-2133.2007.07940.x

PubMed Abstract | Crossref Full Text | Google Scholar

18. Oyama N, Kojima-Ishii K, Toda N, Matsuo T, Tocan V, Ohkubo K, et al. Malignant transformation of phosphaturic mesenchymal tumor: a case report and literature review. Clin Pediatr Endocrinol. (2020) 29:69–75. doi: 10.1297/cpe.29.69

PubMed Abstract | Crossref Full Text | Google Scholar

19. Radaideh ARM, Jaradat D, Abu-Kalaf MM, and Nusier MK. Resolution of severe oncogenic hypophosphatemic osteomalacia after resection of a deeply located soft-tissue tumour. Curr Oncol. (2009) 16:87–90. doi: 10.3747/co.v16i5.412

PubMed Abstract | Crossref Full Text | Google Scholar

20. Shi Z, Deng Y, Li X, Li Y, Cao D, and Coossa V. CT and MR imaging features in phosphaturic mesenchymal tumor-mixed connective tissue: a case report. Oncol Lett. (2018) 15(4):4970–8. doi: 10.3892/ol.2018.7945

PubMed Abstract | Crossref Full Text | Google Scholar

21. McHan L and Augustine M. Two cases of improved bone mineral density following treatment of hypophosphatemic osteomalacia due to FGF23 excess. JCEM Case Rep. (2024) 2:luae073. doi: 10.1210/jcemcr/luae073

PubMed Abstract | Crossref Full Text | Google Scholar

22. Cheung F, Ma L, Wu W, Siu T, Choi P, and Tai Y. Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies. Hong Kong Med J. (2006) 12(4):319–21.

PubMed Abstract | Google Scholar

23. Ferrari M, Palleschi A, Bartoli F, Polli F, Armiraglio E, Parafioriti A, et al. Management of intrathoracic phosphaturic mesenchymal tumor by nonintubated uniportal video-assisted thoracic surgery in a fragile patient. Cancer Rep. (2021) 5:e1500. doi: 10.1002/cnr2.1500

PubMed Abstract | Crossref Full Text | Google Scholar

24. Gascon A. Oncogenic osteomalacia in a patient with a fibrocystic nodule of the breast. Nephrol Dial Transplant. (1999) 14:1561–3. doi: 10.1093/ndt/14.6.1561

PubMed Abstract | Crossref Full Text | Google Scholar

25. Zhang Y, Wang P, and Jing H. Lung nodule as culprit lesion causing recurrent tumor-induced osteomalacia revealed by 68Ga-DOTATATE PET/CT. Clin Nucl Med. (2023) 48:826–7. doi: 10.1097/RLU.0000000000004771

PubMed Abstract | Crossref Full Text | Google Scholar

26. Zhang Y, Xu C, and Yang Y. Tumor-induced osteomalacia with IgG4-related lymph node disease. Chin Med J (Engl). (2019) 132:994–5. doi: 10.1097/CM9.0000000000000188

PubMed Abstract | Crossref Full Text | Google Scholar

27. Krishnappa B, Jadhav SR, Lila AR, and Bandgar TR. Tumour-induced osteomalacia due to an intra-abdominal mesenchymal tumour. BMJ Case Rep. (2019) 12:e231728. doi: 10.1136/bcr-2019-231728

PubMed Abstract | Crossref Full Text | Google Scholar

28. Long Y, Shao F, and Lan X. Mediastinal epithelioid hemangioendothelioma revealed on 68Ga-DOTATATE PET/CT. Clin Nucl Med. (2020) 45:414–6. doi: 10.1097/RLU.0000000000003007

PubMed Abstract | Crossref Full Text | Google Scholar

29. Olivas-Mazón R, Martín-Cazaña M, Pérez-Mohand P, Garzón-Lorenzo L, Espino-Hernández M, Baro-Fernández M, et al. Tumor-induced osteomalacia in an adolescent with an undifferentiated embryonal sarcoma of the liver. Pediatr Blood Cancer. (2020) 67:e28386. doi: 10.1002/pbc.28386

PubMed Abstract | Crossref Full Text | Google Scholar

30. Salim M, Behairy MS, and Barengolts E. TIO associated with hyperparathyroidism: a rarity, a rule, or a novel HPT-PMT syndrome—a case study with literature review. Case Rep Endocrinol. (2021) 2021:1–4. doi: 10.1155/2021/5172131

PubMed Abstract | Crossref Full Text | Google Scholar

31. Todesco A, D’Journo XB, Fabre D, and Boulate D. Extrapleural cervico-manubriotomy and clavicular swing for the management of a mesenchymal tumour of the middle scalenus: an adapted anterior thoracic inlet approach. Interact Cardiovasc Thorac Surg. (2021) 33:266–8. doi: 10.1093/icvts/ivab078

PubMed Abstract | Crossref Full Text | Google Scholar

32. Jimura TT, Sakaguchi K, and Aozasa K. Phosphaturic mesenchymal tumor, mixed connective tissue variant (oncogenic osteomaiacia). Pathol Int. (1996) 46:238–41. doi: 10.1111/j.1440-1827.1996.tb03605.x

PubMed Abstract | Crossref Full Text | Google Scholar

33. Taylor HC, Santa-Cruz D, Teitelbaum SL, Bergfeld MA, and Whyte MP. Assessment of calcitriol and inorganic phosphate therapy before cure of oncogenous osteomalacia by resection of a mixed mesenchymal tumor. Bone. (1988) 9:37–43. doi: 10.1016/8756-3282(88)90025-7

PubMed Abstract | Crossref Full Text | Google Scholar

34. Ewain NS, Alshehri S, and Aladwani MM. Oncogenic osteomalacia as the initial presentation of pleural epithelioid hemangioendothelioma: a case report. Cureus. (2024) 16(12):e75495. doi: 10.7759/cureus.75495

PubMed Abstract | Crossref Full Text | Google Scholar

35. Abrahamsen B, Smith CD, and Minisola S. Epidemiology of tumor-induced osteomalacia in Denmark. Calcif Tissue Int. (2021) 109:147–56. doi: 10.1007/s00223-021-00843-2

PubMed Abstract | Crossref Full Text | Google Scholar

36. Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, and Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int. (2021) 108:128–42. doi: 10.1007/s00223-020-00691-6

PubMed Abstract | Crossref Full Text | Google Scholar

37. Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S, et al. Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int. (2022) 111:367–79. doi: 10.1007/s00223-022-01005-8

PubMed Abstract | Crossref Full Text | Google Scholar

38. Jan De Beur SM, Dahir KM, Imel EA, Zanchetta MB, Williams A, Li Z, et al. Healthcare resource use associated with tumor-induced osteomalacia: a literature review. J Clin Endocrinol Metab. (2024) 110:102–13. doi: 10.1210/clinem/dgae431

PubMed Abstract | Crossref Full Text | Google Scholar

39. Nguyen BD and Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. (1999) 24:130–1. doi: 10.1097/00003072-199902000-00016

PubMed Abstract | Crossref Full Text | Google Scholar

40. De Beur SMJ, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. (2002) 359:761–3. doi: 10.1016/S0140-6736(02)07846-7

PubMed Abstract | Crossref Full Text | Google Scholar

41. Kato A, Nakamoto Y, Ishimori T, Hayakawa N, Ueda M, Temma T, et al. Diagnostic performance of 68Ga-DOTATOC PET/CT in tumor-induced osteomalacia. Ann Nucl Med. (2021) 35:397–405. doi: 10.1007/s12149-021-01575-x

PubMed Abstract | Crossref Full Text | Google Scholar

42. Hou G, Zhang Y, Liu Y, Wang P, Xia W, Xing X, et al. Head-to-head comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with tumor-induced osteomalacia: a prospective study. Front Oncol. (2022) 12:811209. doi: 10.3389/fonc.2022.811209

PubMed Abstract | Crossref Full Text | Google Scholar

43. Jing H, Li F, Zhuang H, Wang Z, Tian J, Xing X, et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. Eur J Radiol. (2013) 82:2028–34. doi: 10.1016/j.ejrad.2013.04.006

PubMed Abstract | Crossref Full Text | Google Scholar

44. Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract. (2011) 17:177–84. doi: 10.4158/EP10151.OR

PubMed Abstract | Crossref Full Text | Google Scholar

45. Yu W-J, He J-W, Fu W-Z, Wang C, and Zhang Z-L. Reports of 17 chinese patients with tumor-induced osteomalacia. J Bone Miner Metab. (2017) 35:298–307. doi: 10.1007/s00774-016-0756-9

PubMed Abstract | Crossref Full Text | Google Scholar

46. Sun Z, Jin J, Qiu G, Gao P, and Liu Y. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord. (2015) 16:43. doi: 10.1186/s12891-015-0496-3

PubMed Abstract | Crossref Full Text | Google Scholar

47. Florenzano P, Gafni RI, and Collins MT. Tumor-induced osteomalacia. Bone Rep. (2017) 7:90–7. doi: 10.1016/j.bonr.2017.09.002

PubMed Abstract | Crossref Full Text | Google Scholar

48. Crotti C, Zucchi F, Alfieri C, Caporali R, and Varenna M. Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int. (2023) 34:201–6. doi: 10.1007/s00198-022-06516-6

PubMed Abstract | Crossref Full Text | Google Scholar

49. Liu S, Zhou X, Liu Y, Zhang J, and Xia W. Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia. J Bone Oncol. (2024) 45:100600. doi: 10.1016/j.jbo.2024.100600

PubMed Abstract | Crossref Full Text | Google Scholar

50. Weidner N and Cruz DS. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. (1987) 59:1442–54. doi: 10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q

Crossref Full Text | Google Scholar

51. Zuo Q, Wang H, Li W, Niu X, Huang Y, Chen J, et al. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskelet Disord. (2017) 18:403. doi: 10.1186/s12891-017-1756-1

PubMed Abstract | Crossref Full Text | Google Scholar

52. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. (2004) 28:1–30. doi: 10.1097/00000478-200401000-00001

PubMed Abstract | Crossref Full Text | Google Scholar

53. Li D, Wu H, Li J, Xia W, Jiang Y, and Zhong D. Clinical and immunohistopathologic study of phosphaturic mesenchymal tumor. Chin J Pathol. (2018) 47:427–31. doi: 10.3760/cma.j.issn.0529-5807.2018.06.008

PubMed Abstract | Crossref Full Text | Google Scholar

54. Agaimy A, Michal M, Hadravsky L, and Schmolders J. Phosphaturic Mesenchymal Tumors: Clinicopathologic, Immunohistochemical and Molecular Analysis of 22 Cases Expanding their Morphologic and Immunophenotypic Spectrum. Am J Surg Pathol. (2017) 41(10):1371–80. doi: 10.1097/PAS.0000000000000890

PubMed Abstract | Crossref Full Text | Google Scholar

55. Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. (2013) 44:2711–8. doi: 10.1016/j.humpath.2013.07.016

PubMed Abstract | Crossref Full Text | Google Scholar

56. Matthews Y, McKenzie C, Byrne C, and Kench JG. Intraductal tubulopapillary neoplasm of pancreas with associated invasive carcinoma, lymph node, rectal and hepatic metastases. Pathol (Phila). (2015) 47:169–71. doi: 10.1097/PAT.0000000000000228

PubMed Abstract | Crossref Full Text | Google Scholar

57. Shiba E, Matsuyama A, Shibuya R, Yabuki K, Harada H, Nakamoto M, et al. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. Diagn Pathol. (2016) 11:26. doi: 10.1186/s13000-016-0477-3

PubMed Abstract | Crossref Full Text | Google Scholar

58. Wu H, Bui MM, Zhou L, Li D, Zhang H, and Zhong D. Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review. Mod Pathol. (2019) 32:189–204. doi: 10.1038/s41379-018-0100-0

PubMed Abstract | Crossref Full Text | Google Scholar

59. Wang F, He W, Ma D, Xu W, Xie J, and Yuan G. Sphenoid sinus is a rare site for tumor-induced osteomalacia: a case report and literature review. Front Endocrinol. (2023) 14:1116793. doi: 10.3389/fendo.2023.1116793

PubMed Abstract | Crossref Full Text | Google Scholar

60. Chatterjee D, Bardia A, Pal R, Saikia UN, Bhadada SK, and Radotra BD. Clinical, morphological and immunohistochemical analysis of 13 cases of phosphaturic mesenchymal tumor - a holistic diagnostic approach. Ann Diagn Pathol. (2021) 54:151783. doi: 10.1016/j.anndiagpath.2021.151783

PubMed Abstract | Crossref Full Text | Google Scholar

61. Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, et al. Tumor-induced osteomalacia: a comprehensive review. Endocr Rev. (2023) 44:323–53. doi: 10.1210/endrev/bnac026

PubMed Abstract | Crossref Full Text | Google Scholar